{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:22:47Z","timestamp":1789100567494,"version":"build-2803163510"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T00:00:00Z","timestamp":1543190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s40273-018-0749-8","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T01:40:27Z","timestamp":1543196427000},"page":"119-130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Future Costs in Cost-Effectiveness Analyses: Past, Present, Future"],"prefix":"10.1007","volume":"37","author":[{"given":"Linda M.","family":"de Vries","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter H. M.","family":"van Baal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner B. F.","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,26]]},"reference":[{"key":"749_CR1","first-page":"471","volume-title":"Handbook of health economics","author":"AM Garber","year":"2011","unstructured":"Garber AM, Sculpher MJ. Chapter eight: cost effectiveness and payment policy. In: Pauly MV, Mcguire TG, Barros PP, editors. Handbook of health economics, vol. 2. Amsterdam: Elsevier; 2011. p. 471\u201397."},{"issue":"10","key":"749_CR2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2165\/00019053-200826100-00003","volume":"26","author":"DR Rappange","year":"2008","unstructured":"Rappange DR, et al. Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions? Pharmacoeconomics. 2008;26(10):815\u201330.","journal-title":"Pharmacoeconomics."},{"issue":"7","key":"749_CR3","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s10198-017-0947-x","volume":"19","author":"LI Lier van","year":"2018","unstructured":"van Lier LI, et al. Consensus-based cross-European recommendations for the identification, measurement and valuation of costs in health economic evaluations: a European Delphi study. Eur J Health Econ. 2018;19(7):993\u20131008.","journal-title":"Eur J Health Econ."},{"key":"749_CR4","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, et al. Methods for the economic evaluation of health care programmes. 4th ed. New York: Oxford University Press; 2015.","edition":"4"},{"issue":"1","key":"749_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0167-6296(96)00506-1","volume":"16","author":"AM Garber","year":"1997","unstructured":"Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ. 1997;16(1):1\u201331.","journal-title":"J Health Econ."},{"issue":"1","key":"749_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0167-6296(96)00507-3","volume":"16","author":"D Meltzer","year":"1997","unstructured":"Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ. 1997;16(1):33\u201364.","journal-title":"J Health Econ."},{"issue":"5","key":"749_CR7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/hec.850","volume":"13","author":"JA Nyman","year":"2004","unstructured":"Nyman JA. Should the consumption of survivors be included as a cost in cost-utility analysis? Health Econ. 2004;13(5):417\u201327.","journal-title":"Health Econ."},{"key":"749_CR8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/hec.1067","volume":"15","author":"JA Nyman","year":"2006","unstructured":"Nyman JA. More on survival consumption costs in cost-utility analysis. Health Econ. 2006;15:319\u201322.","journal-title":"Health Econ."},{"key":"749_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/hec.1066","volume":"15","author":"JR Richardson","year":"2006","unstructured":"Richardson JR, Olsen JA. In defence of societal sovereignty: a comment on Nyman \u2018the inclusion of survivor consumption in CUA\u2019. Health Econ. 2006;15:311\u20133.","journal-title":"Health Econ."},{"key":"749_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/hec.1065","volume":"15","author":"A Gandjour","year":"2006","unstructured":"Gandjour A. Consumption costs and earnings during added years of life: a reply to Nyman. Health Econ. 2006;15:315\u20137.","journal-title":"Health Econ."},{"key":"749_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/hec.1290","volume":"17","author":"D Lundin","year":"2008","unstructured":"Lundin D, Ramsberg J. On survival consumption costs: a reply to Nyman. Health Econ. 2008;17:293\u20137.","journal-title":"Health Econ."},{"key":"749_CR12","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/hec.1181","volume":"16","author":"PHM Baal van","year":"2007","unstructured":"van Baal PHM, et al. Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a \u201cperfect\u201d cost-utility ratio. Health Econ. 2007;16:421\u201333.","journal-title":"Health Econ."},{"key":"749_CR13","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/hec.1279","volume":"17","author":"B Liljas","year":"2008","unstructured":"Liljas B, Karlsson GS, Stalhammar N. On future non-medical costs in economic evaluations. Health Econ. 2008;17:579\u201391.","journal-title":"Health Econ."},{"key":"749_CR14","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jhealeco.2007.09.011","volume":"27","author":"RH Lee","year":"2008","unstructured":"Lee RH. Future costs in cost effectiveness analysis. J Health Econ. 2008;27:809\u201318.","journal-title":"J Health Econ."},{"key":"749_CR15","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.jhealeco.2008.05.001","volume":"27","author":"D Meltzer","year":"2008","unstructured":"Meltzer D. Response to \u201cFuture costs and the future of cost-effectiveness analysis\u201d. J Health Econ. 2008;27:822\u20135.","journal-title":"J Health Econ."},{"issue":"6","key":"749_CR16","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.jhealeco.2008.07.007","volume":"27","author":"TL Feenstra","year":"2008","unstructured":"Feenstra TL, et al. Future costs in economic evaluation: a comment on Lee. J Health Econ. 2008;27(6):1645\u20139.","journal-title":"J Health Econ."},{"issue":"1","key":"749_CR17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/hec.1567","volume":"20","author":"JA Nyman","year":"2011","unstructured":"Nyman JA. Measurement of QALYS and the welfare implications of survivor consumption and leisure forgone. Health Econ. 2011;20(1):56\u201367.","journal-title":"Health Econ."},{"issue":"1","key":"749_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/hec.1600","volume":"20","author":"B Liljas","year":"2011","unstructured":"Liljas B. Welfare, QALYS, and costs: a comment. Health Econ. 2011;20(1):68\u201372.","journal-title":"Health Econ."},{"issue":"2","key":"749_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/hec.3138","volume":"25","author":"PHM Baal van","year":"2016","unstructured":"van Baal PHM, Meltzer D, Brouwer W. Future costs, fixed healthcare budgets, and the decision rules of cost-effectiveness analysis. Health Econ. 2016;25(2):237\u201348.","journal-title":"Health Econ."},{"issue":"8","key":"749_CR20","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/hec.3366","volume":"25","author":"A Morton","year":"2016","unstructured":"Morton A, et al. Unrelated future costs and unrelated future benefits: reflections on NICE guide to the methods of technology appraisal. Health Econ. 2016;25(8):933\u20138.","journal-title":"Health Econ."},{"key":"749_CR21","doi-asserted-by":"publisher","unstructured":"van Baal P, et al. Future unrelated medical costs need to be considered in cost-effectiveness analysis. Eur J Health Econ. https:\/\/doi.org\/10.1007\/s10198-018-0976-0 . (Epub ahead of print).","DOI":"10.1007\/s10198-018-0976-0"},{"issue":"2","key":"749_CR22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jhealeco.2007.07.003","volume":"27","author":"WB Brouwer","year":"2008","unstructured":"Brouwer WB, et al. Welfarism vs. extra-welfarism. J Health Econ. 2008;27(2):325\u201338.","journal-title":"J Health Econ."},{"issue":"2","key":"749_CR23","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0047-2727(73)90002-9","volume":"2","author":"M Weinstein","year":"1973","unstructured":"Weinstein M, Zeckhauser R. Critical ratios and efficient allocation. J Public Econ. 1973;2(2):147\u201357.","journal-title":"J Public Econ."},{"issue":"4","key":"749_CR24","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1177\/0272989X9901900401","volume":"19","author":"D Meltzer","year":"1999","unstructured":"Meltzer D, Johannesson M. Inconsistencies in the \u2018societal perspective\u2019 on costs of the panel on cost-effectiveness in health and medicine. Med Decis Mak. 1999;19(4):371\u20137.","journal-title":"Med Decis Mak."},{"key":"749_CR25","volume-title":"Economic analysis in health care","author":"S Morris","year":"2007","unstructured":"Morris S, Devlin N, Parkin D. Economic analysis in health care. Chichester: Wiley; 2007."},{"issue":"11","key":"749_CR26","doi-asserted-by":"publisher","first-page":"981","DOI":"10.2165\/11599390-000000000-00000","volume":"30","author":"DT Grima","year":"2012","unstructured":"Grima DT, et al. Cost-effectiveness analysis of therapies: a case for excluding dialysis costs. Pharmacoeconomics. 2012;30(11):981\u20139.","journal-title":"Pharmacoeconomics."},{"issue":"5","key":"749_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s40273-013-0042-9","volume":"31","author":"PHM Baal van","year":"2013","unstructured":"van Baal PHM, Meltzer D, Brouwer W, et al. Pharmacoeconomic guidelines should prescribe inclusion of indirect medical costs! A response to Grima et al. Pharmacoeconomics. 2013;31(5):369\u201373.","journal-title":"Pharmacoeconomics."},{"issue":"15","key":"749_CR28","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","volume":"276","author":"MC Weinstein","year":"1996","unstructured":"Weinstein MC, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276(15):1253\u20138.","journal-title":"JAMA."},{"issue":"359","key":"749_CR29","doi-asserted-by":"publisher","first-page":"j5096","DOI":"10.1136\/bmj.j5096","volume":"10","author":"P Baal van","year":"2017","unstructured":"van Baal P, et al. Should cost effectiveness analyses for NICE always consider future unrelated medical costs? BMJ. 2017;10(359):j5096. https:\/\/doi.org\/10.1136\/bmj.j5096 .","journal-title":"BMJ."},{"issue":"1","key":"749_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1524-4733.2003.00234.x","volume":"6","author":"MC Weinstein","year":"2003","unstructured":"Weinstein MC, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices\u2014modeling studies. Value Health. 2003;6(1):9\u201317.","journal-title":"Value Health."},{"issue":"2","key":"749_CR31","doi-asserted-by":"publisher","first-page":"e1002232","DOI":"10.1371\/journal.pmed.1002232","volume":"14","author":"LJ Cobiac","year":"2017","unstructured":"Cobiac LJ, et al. Taxes and subsidies for improving diet and population health in Australia: a cost-effectiveness modelling study. PLoS Med. 2017;14(2):e1002232. https:\/\/doi.org\/10.1371\/journal.pmed.1002232 .","journal-title":"PLoS Med."},{"issue":"7","key":"749_CR32","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/j.1524-4733.2008.00328.x","volume":"11","author":"PH Baal van","year":"2008","unstructured":"van Baal PH, et al. Cost-effectiveness of a low-calorie diet and orlistat for obese persons: modeling long-term health gains through prevention of obesity-related chronic diseases. Value Health. 2008;11(7):1033\u201340.","journal-title":"Value Health."},{"issue":"15","key":"749_CR33","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1056\/NEJM199710093371506","volume":"337","author":"JJ Barendregt","year":"1997","unstructured":"Barendregt JJ, Bonneux L, van der Maas PJ. The health care costs of smoking. N Engl J Med. 1997;337(15):1052\u20137.","journal-title":"N Engl J Med."},{"issue":"2","key":"749_CR34","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.jhealeco.2004.11.009","volume":"24","author":"A Gandjour","year":"2005","unstructured":"Gandjour A, Lauterbach KW. Does prevention save costs? Considering deferral of the expensive last year of life. J Health Econ. 2005;24(2):715\u201324.","journal-title":"J Health Econ."},{"issue":"3","key":"749_CR35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2165\/11586130-000000000-00000","volume":"29","author":"PHM Baal van","year":"2011","unstructured":"van Baal PHM, et al. Standardizing the inclusion of indirect medical costs in economic evaluations. Pharmacoeconomics. 2011;29(3):175\u201387.","journal-title":"Pharmacoeconomics."},{"issue":"6","key":"749_CR36","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/(SICI)1099-1050(199909)8:6<485::AID-HEC461>3.0.CO;2-4","volume":"8","author":"P Zweifel","year":"1999","unstructured":"Zweifel P, Felder S, Meiers M. Ageing of population and health care expenditure: a red herring? Health Econ. 1999;8(6):485\u201396.","journal-title":"Health Econ."},{"issue":"4","key":"749_CR37","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/hec.1599","volume":"20","author":"PHM Baal van","year":"2011","unstructured":"van Baal PHM, et al. Economic evaluation and the postponement of health care costs. Health Econ. 2011;20(4):432\u201345.","journal-title":"Health Econ."},{"key":"749_CR38","volume-title":"Health care costs in the English NHS: reference tables for average annual NHS spend by age, sex and deprivation group. CHE research paper 147","author":"M Assaria","year":"2017","unstructured":"Assaria M. Health care costs in the English NHS: reference tables for average annual NHS spend by age, sex and deprivation group. CHE research paper 147. York: Centre for Health Economics, University of York; 2017."},{"key":"749_CR39","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ypmed.2016.01.013","volume":"85","author":"PH Baal van","year":"2016","unstructured":"van Baal PH, Hoogendoorn M, Fischer A. Preventing dementia by promoting physical activity and the long-term impact on health and social care expenditures. Prev Med. 2016;85:78\u201383.","journal-title":"Prev Med."},{"issue":"5","key":"749_CR40","doi-asserted-by":"publisher","first-page":"e0197257","DOI":"10.1371\/journal.pone.0197257","volume":"13","author":"ADM Briggs","year":"2018","unstructured":"Briggs ADM, et al. Estimating comparable English healthcare costs for multiple diseases and unrelated future costs for use in health and public health economic modelling. PLoS One. 2018;13(5):e0197257. https:\/\/doi.org\/10.1371\/journal.pone.0197257 .","journal-title":"PLoS One."},{"key":"749_CR41","volume-title":"The Elgar companion to health economics","author":"D Meltzer","year":"2012","unstructured":"Meltzer D. Future costs in medical cost-effectiveness analysis. In: Jones AM, editor. The Elgar companion to health economics. 2nd ed. Cheltenham: Edward Elgar; 2012.","edition":"2"},{"key":"749_CR42","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10198-010-0280-0","volume":"13","author":"M Kruse","year":"2012","unstructured":"Kruse M, Sorensen J, Gyrd-Hansen D. Future costs in cost-effectiveness analysis: an empirical assessment. Eur J Health Econ. 2012;13:63\u201370.","journal-title":"Eur J Health Econ."},{"issue":"4","key":"749_CR43","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1177\/0272989X9701700403","volume":"17","author":"M Johannesson","year":"1997","unstructured":"Johannesson M, Meltzer D, O\u2019Conor RM. Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension. Med Decis Mak. 1997;17(4):382\u20139.","journal-title":"Med Decis Mak."},{"issue":"11","key":"749_CR44","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/hec.790","volume":"12","author":"B Manns","year":"2003","unstructured":"Manns B, et al. Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care. Health Econ. 2003;12(11):949\u201358.","journal-title":"Health Econ."},{"issue":"6","key":"749_CR45","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1097\/00005650-200006000-00009","volume":"38","author":"D Meltzer","year":"2000","unstructured":"Meltzer D, et al. Effect of future costs on cost-effectiveness of medical interventions among young adults: the example of intensive therapy for type 1 diabetes mellitus. Med Care. 2000;38(6):679\u201385.","journal-title":"Med Care."},{"issue":"10","key":"749_CR46","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.jval.2017.05.013","volume":"20","author":"IC Ramos","year":"2017","unstructured":"Ramos IC, et al. Cost effectiveness of the angiotensin receptor neprilysin inhibitor sacubitril\/valsartan for patients with chronic heart failure and reduced ejection fraction in the Netherlands: a country adaptation analysis under the former and current Dutch. Value Health. 2017;20(10):1260\u20139.","journal-title":"Value Health."},{"issue":"6","key":"749_CR47","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0167-6296(99)00014-4","volume":"18","author":"H Bleichrodt","year":"1999","unstructured":"Bleichrodt H, Quiggin J. Life-cycle preferences over consumption and health: when is cost-effectiveness analysis equivalent to cost\u2013benefit analysis? J Health Econ. 1999;18(6):681\u2013708.","journal-title":"J Health Econ."},{"issue":"3","key":"749_CR48","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1257\/jep.20.3.97","volume":"20","author":"D Cutler","year":"2006","unstructured":"Cutler D, Deaton A, Lleras-Muney A. The determinants of mortality. J Econ Perspect. 2006;20(3):97\u2013120.","journal-title":"J Econ Perspect."},{"issue":"2","key":"749_CR49","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1524-4733.2009.00614.x","volume":"13","author":"C Tilling","year":"2010","unstructured":"Tilling C, et al. In or out? Income losses in health state valuations: a review. Value Health. 2010;13(2):298\u2013305.","journal-title":"Value Health."},{"issue":"2","key":"749_CR50","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/hec.3162","volume":"25","author":"CC Adarkwah","year":"2016","unstructured":"Adarkwah CC, Sadoghi A, Gandjour A. Should cost-effectiveness analysis include the cost of consumption activities? An empirical investigation. Health Econ. 2016;25(2):249\u201356.","journal-title":"Health Econ."},{"issue":"1","key":"749_CR51","doi-asserted-by":"publisher","first-page":"238146831876516","DOI":"10.1177\/2381468318765162","volume":"3","author":"J Nyman","year":"2018","unstructured":"Nyman J. Cost recommendations in the second edition of cost-effectiveness in health and medicine: a review. MDM Policy Pract. 2018;3(1):2381468318765162. https:\/\/doi.org\/10.1177\/2381468318765162 .","journal-title":"MDM Policy Pract"},{"issue":"2","key":"749_CR52","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1017\/S0266462317000526","volume":"33","author":"RMWA Drost","year":"2017","unstructured":"Drost RMWA, et al. Conceptualizations of the societal perspective within economic evaluations: a systematic review. Int J Technol Assess Health Care. 2017;33(2):251\u201360.","journal-title":"Int J Technol Assess Health Care."},{"key":"749_CR53","unstructured":"Ekman M. Consumption and production by age in Sweden: basic facts and health economic implications. Studies in health economics: modelling and data analysis of costs and survival. Stockholm: Stockholm School of Economics; 2002."},{"key":"749_CR54","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195108248.001.0001","volume-title":"Cost-effectiveness in health and medicine","author":"MR Gold","year":"1996","unstructured":"Gold MR, et al. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 1996."},{"issue":"5","key":"749_CR55","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3109\/0284186X.2015.1096021","volume":"55","author":"S Borg","year":"2016","unstructured":"Borg S, et al. Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden. Acta Oncol. 2016;55(5):554\u201360.","journal-title":"Acta Oncol."},{"issue":"3","key":"749_CR56","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1586\/14737167.2015.1021689","volume":"15","author":"B Gros","year":"2015","unstructured":"Gros B, Soto \u00c1lvarez J, \u00c1ngel Casado M. Incorporation of future costs in health economic analysis publications: current situation and recommendations for the future. Expert Rev Pharmacoecon Outcomes Res. 2015;15(3):465\u20139.","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"key":"749_CR57","unstructured":"Zorginstituut Nederland. Guideline for economic evaluations in healthcare. 2016."},{"key":"749_CR58","unstructured":"The Dental and Pharmaceutical Benefits Agency. General guidelines for economic evaluations. 2003."},{"issue":"2","key":"749_CR59","doi-asserted-by":"publisher","first-page":"41","DOI":"10.5617\/njhe.1592","volume":"5","author":"M Svensson","year":"2017","unstructured":"Svensson M, Hultkrantz L. A comparison of cost-benefit and cost-effectiveness analysis in practice: divergent policy practices in Sweden. Nordic J Health Econ. 2017;5(2):41\u201353.","journal-title":"Nordic J Health Econ."},{"issue":"7","key":"749_CR60","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.zefq.2014.09.006","volume":"108","author":"E Heintz","year":"2014","unstructured":"Heintz E, et al. The impact of health economic evaluations in Sweden. Z Evid Fortbild Qual Gesundh. 2014;108(7):375\u201382.","journal-title":"Z Evid Fortbild Qual Gesundh."},{"key":"749_CR61","doi-asserted-by":"crossref","unstructured":"Davidson T. Experiences of including costs of added life years in health economic evaluations in Sweden. In: Pirhonen L, Davidson T, editors. Farmeconomia: health economics and therapeutic pathways. 2014;15(2):45\u201353.","DOI":"10.7175\/fe.v15i2.925"},{"key":"749_CR62","unstructured":"The Dental and Pharmaceutical Benefits Agency. \u00c4ndring i L\u00e4kemedelsf\u00f6rm\u00e5nsn\u00e4mndens allm\u00e4nna r\u00e5d (LFNAR 2003:2) om ekonomiska utv\u00e4rderingar. 2015."},{"key":"749_CR63","unstructured":"\u00c4ndring i Tandv\u00e5rds - och l\u00e4kemedelsf\u00f6rm\u00e5nsverkets allm\u00e4nna r\u00e5d (TLVAR 2003:2) om ekonomiska utv\u00e4rderingar. 2017."},{"issue":"10","key":"749_CR64","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093\u2013103.","journal-title":"JAMA."},{"key":"749_CR65","first-page":"433","volume-title":"Handbook of health economics","author":"DO Meltzer","year":"2011","unstructured":"Meltzer DO, Smith PC. Chapter seven: theoretical issues relevant to the economic evaluation of health technologies. In: Pauly MV, Mcguire TG, Barros PP, editors. Handbook of health economics, vol. 2. Amsterdam: Elsevier; 2011. p. 433\u201369."},{"key":"749_CR66","volume-title":"Guide to the methods of technology appraisal","author":"National Institute for Health and Clinical Excellence (NICE)","year":"2013","unstructured":"National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. London: NICE; 2013."},{"key":"749_CR67","volume-title":"Is prevention better than cure? Washington","author":"LB Russell","year":"1986","unstructured":"Russell LB. Is prevention better than cure? Washington. DC: Brookings Institution; 1986."},{"key":"749_CR68","doi-asserted-by":"publisher","unstructured":"Nord E, Lam\u00f8y C. Including future consumption and production in economic evaluation of interventions that save life-years: commentary. Pharmacoecon Open. 2018. https:\/\/doi.org\/10.1007\/s41669-018-0079-y . (Epub ahead of print).","DOI":"10.1007\/s41669-018-0079-y"},{"issue":"6","key":"749_CR69","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.healthpol.2018.04.001","volume":"122","author":"VT Reckers-Droog","year":"2018","unstructured":"Reckers-Droog VT, van Exel NJA, Brouwer WBF. Looking back and moving forward: on the application of proportional shortfall in healthcare priority setting in the Netherlands. Health Policy. 2018;122(6):621\u20139.","journal-title":"Health Policy."},{"key":"749_CR70","doi-asserted-by":"publisher","unstructured":"van Baal P, et al. A cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending. Health Econ. 2018. https:\/\/doi.org\/10.1002\/hec.3831 . (Epub ahead of print).","DOI":"10.1002\/hec.3831"},{"key":"749_CR71","doi-asserted-by":"crossref","unstructured":"Brouwer WBF, et al. When is it too expensive? Cost-effectiveness thresholds and health care decision making. Eur J Health Econ. 2018.","DOI":"10.1007\/s10198-018-1000-4"},{"issue":"5","key":"749_CR72","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1524-4733.2006.00123.x","volume":"9","author":"WBF Brouwer","year":"2006","unstructured":"Brouwer WBF, Baltussen M, Rutten FFH. A dollar is a dollar is a dollar: or is it? Value Health. 2006;9(5):341\u20137.","journal-title":"Value Health."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-018-0749-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0749-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-018-0749-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T19:02:47Z","timestamp":1720810967000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-018-0749-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,26]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["749"],"URL":"https:\/\/doi.org\/10.1007\/s40273-018-0749-8","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,26]]},"assertion":[{"value":"26 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Linda M. de Vries, Pieter H.M. van Baal, and Werner B.F. Brouwer have no conflicts of interest that are directly relevant to the contents of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}